RxDoctor Payments Data

Carolyn Amonette, NP

Family · Nashville, TNNPI 1376117754

Payments from drug & device makers

$1,051in general payments, 2019–2025

Across 12 payments — averaging $87.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$411
  • Medtronic$181
  • Photocure Inc$149
  • Sumitomo Pharma America, Inc.$125
  • Johnson & Johnson$69
  • Antares Pharma, Inc.$44
  • plus $72 from 3 others

What the payments were for

  • Speaking & faculty fees$12512%
  • Food & beverage$92688%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Coloplast4$411
Medtronic1$181
Photocure Inc1$149
Sumitomo Pharma America, Inc.1$125
Johnson & Johnson1$69
Antares Pharma, Inc.1$44
Astellas Pharma US Inc1$43
Rochester Medical Corporation1$15
Endo USA, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,051 in reported general payments places this provider in the 65th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$74,695
Medicare patients
461
Services billed
2,076

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron273$257,172
MyrbetriqMirabegron121$123,695
Estradiol188$15,166
Trospium Chloride130$9,507
Trospium Chloride ErTrospium Chloride22$4,764
Methenamine Hippurate57$4,330
Tamsulosin Hcl249$3,685
Fosfomycin Tromethamine24$3,087
Solifenacin Succinate50$2,526
Testosterone12$2,174
Finasteride164$2,115
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst83$1,610
Doxazosin Mesylate53$1,009
Testosterone Cypionate31$619
Lidocaine13$273

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$125$257,172273 claims
Astellas Pharma US IncMyrbetriq$43$123,695121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 6,706 family providers in Tennessee.

Other family in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →